Lilly’s $400 Billion Surge Reshapes Big Pharma, Rally
Eli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
Overview of annual performance metrics for index funds highlights consistency and risk-adjusted returns to inform choices.
21,677 articlesEli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
Micron Technology is signaling a blockbuster earnings trajectory as AI workloads fuel memory demand, with guidance po...
As AI fuels data-center growth, two infrastructure players stand out: Argan and Comfort Systems USA. This guide break...
Ratepayers may be paying more as grid upgrades to support data centers roll out. A PJM-wide assessment estimates roug...
Stocks hover near record highs as earnings show resilience, but analysts warn that the gap between prices and profits...
Joe Biden’s forthcoming memoir, Promise Me, America, lands November 17, two weeks after the midterms. The release cou...
New data shows ULTY's steep cost, via a 1.24% expense ratio, quietly chewing into returns even as distributions persi...
A veteran investor casts Broadcom as a core AI winner, arguing durable AI demand and strategic partnerships could kee...
Air-taxi darlings Joby, Archer, and EHang have fallen sharply in 2026 as cert timelines and cash burn loom large. Inv...
Berkshire Hathaway’s surprise Alphabet investment signals a bold, long-term bet from Buffett. Learn the reasoning, ri...
Netflix stock down 2026 has investors weighing a sizable pullback against the company’s long-term growth story. This ...